September's financial landscape is marked by rising global bond yields and persistent inflation, challenging long-duration assets and testing the Federal Reserve's policy credibility. Geopolitical tensions between Iran and Saudi Arabia threaten oil supplies, potentially triggering an energy-driven inflation shock. Equities face volatility from AI-driven sector concentration and financing risks, while economic bottlenecks shift value toward trust, security, and legal accountability sectors. With 10-year Treasury yields near 5%, investors are advised to focus on high-quality fixed income and resilient, cash-generative businesses to navigate macroeconomic uncertainty and elevated interest rates.
The story on yield surges and energy shocks is set against a backdrop of active US stock trading on Pluang. For readers following US equities, here is Pluang's market snapshot as of Sep 17, 2026 22:21 WIB: out of 150 priced US stocks, 102 rose and 46 fell. Notable movers include FCEL at USD 17.50 (+12.90%), NVAX at USD 10.18 (+8.82%), and INTC at USD 109.63 (+8.49%).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
